

Practitioner's Docket No. MWH-0006US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Denton, R. Rex; Kliem, Stefanie E.; Nandabalan, Krishnan; and
Stephens, J. Claiborne

#3 / I.D.S

Application No.: To Be Assigned
Filed: February 06, 2002

Group No.: 1632
Examiner: Anne-Marie Baker, Ph.D.


For: Drug Target Isogenes: Polymorphisms in the 5-Hydroxytryptamine Receptor 1A Gene

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).



Gisela M. Field
Genaissance Pharmaceuticals, Inc.
5 Science Park
New Haven, CT 06511
USA

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	February 6, 2002
		First Named Inventor	R. Rex Denton
		Group Art Unit	1632
		Examiner Name	Anne-Marie Baker
		Attorney Docket Number	MWH-0006US
Sheet	1	of	1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	INAYAMA, Y. ET AL., "Positive Association Between a DNA Sequence Variant in the Serotonin 2A Receptor Gene and Schizophrenia," Am. J. Med. Genet., Vol. 67, p.103-105, (1996).	
	AB	KAWANISHI, Y. ET AL., "Novel Mutations in the Promoter and Coding Region of the Human 5-HT1A Receptor Gene and Association Analysis in Schizophrenia," Am. J. Med. Genet, Vol. 81, p. 434-439, (1998).	
	AC	KHAN, M. ET AL., "A SacI RFLP is Detected with the 5-HT1A Serotonin Receptor Probe G21," Nucleic Acids Research, Vol. 18 (No.3), p. 691, (1990).	
	AD	KOBILKA, B. ET AL., "An Intronless Gene Encoding a Potential Member of the Family of Receptors Coupled to Guanine Nucleotide Regulatory Proteins," Nature, Vol. 329, p. 75-79, (1987).	
	AE	LAM, S. ET AL., "A Serotonin Receptor Gene (5HT1A) Variant Found in a Tourette's Syndrome Patient," Biochemical and Biophysical Research Communications, Vol. 219, p. 853-858, (1996).	
	AF	MELMER, G. ET AL., "A Cosmid Clone for the 5HT1A Receptor (HTR1A) Reveals a TaqI RFLP That Shows Tight Linkage to DNA Loci D5S6, D5S39, and D5s76," Genomics, Vol. 11, p. 767-769, (1991).	
	AG	NAKHAI, B. ET AL., "Two Naturally Occurring Amino Acid Substitutions in the Human 5-HT1A Receptor: Glycine 22 to Serine 22 and Isoleucine 28 to Valine 28," Biochemical and Biophysical Research Communications, Vol. 210 (No.2), p. 530-536, (1995).	
	AH	PARKS, C. AND THOMAS SHENK, "The Serotonin 1a Receptor Gene contains a TATA-less Promoter that Responds to MAZ and Sp1," J. Biol. Chem., Vol. 271 (No.8), p. 4417-4430, (1996).	
	AI	WARREN JR., J. ET AL., "An RsaI Polymorphism in the Human Serotonin Receptor Gene (HTR1A): Detection by DGGE and RFLP Analysis," Human Molecular Genetics, Vol. 1 (No. 9), p. 778, (1992).	
	AJ	XIE, D. ET AL., "The Gene Encoding the 5-HT1A Receptor is Intact in Mood Disorders," Neuropsychopharmacology, Vol. 12 (No.3), p. 263-268, (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.